Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Coherus Oncology Inc (Coherus) is a commercial-stage biopharmaceutical company that focuses on research, development, and commercialization of innovative immunotherapies to treat cancer. Its pipeline products include LOQTORZI (toripalimab-tpzi), a novel PD-1 inhibitor, that treats nasopharyngeal carcinoma; Casdozokitug is an investigational recombinant human IgG1 monoclonal antibody for hepatocellular carcinoma; Tagmokitug, an anti-CCR8 monoclonal antibody which treats colorectal cancer, head and neck squamous cell carcinoma, gastric cancer, erythema annulare centrifugum, esophageal squamous cell carcinoma and metastatic castration-resistant prostate cancer. It has operations across the US. Coherus is headquartered in Redwood City, California, the US.
Headquarters
United States of America
Address
C/O Dennis M. Lanfear, 201 Redwood Shores Parkway, Suite 200, Redwood City, California, 94065
Website
www.coherus.com
Telephone
1 800 7945434
No of Employees
145
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CHRS (NASD)
Revenue (2024)
$42.2M
59.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
489.4%
(2024 vs 2023)
Market Cap*
$223.7M
Net Profit Margin (2024)
XYZ
268.8%
(2024 vs 2023)
* As of and is in US$
Coherus Oncology Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | LOQTORZI |
| LOQTORZI (toripalimab-tpzi): Nasopharyngeal Carcinoma | |
| Casdozokitug: Hepatocellular Carcinoma | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Divestiture | In August, the company sold UDENYCA (pegfilgrastim-cbqv) to Intas Pharmaceuticals Ltd. |
| 2025 | Corporate Changes/Expansions | In May, the company rebranded to Coherus Oncology Inc. |
| 2025 | Divestiture | In April, the company sold its UDENYCA (pegfilgrastim-cbqv) franchise (the Transaction) to Intas Pharmaceuticals Ltd. for US$558.4 million. |
Competitor Comparison
| Key Parameters | Coherus Oncology Inc | Merck & Co Inc | Pfizer Inc | AbbVie Inc | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United Kingdom |
| City | Redwood City | Rahway | New York City | North Chicago | Cambridge |
| State/Province | California | New Jersey | New York | Illinois | Cambridgeshire |
| No. of Employees | 145 | 75,000 | 75,000 | 57,000 | 96,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dennis M. Lanfear | President; Chairman; Chief Executive Officer | Executive Board | 2010 | 70 |
| Bryan McMichael | Chief Financial Officer | Senior Management | 2024 | 47 |
| Andy Rittenberg | Chief Legal Officer | Senior Management | 2024 | - |
| Rosh Dias, M.D | Chief Medical Officer | Senior Management | 2022 | - |
| Arvind Sood | Chief Strategy and Corporate Affairs Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer